JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
122.29
-0.28 (-0.23%)
As of 11:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close122.57
Open122.42
Bid122.24 x 800
Ask122.23 x 1100
Day's Range121.66 - 122.66
52 Week Range118.62 - 148.32
Volume2,034,987
Avg. Volume6,659,493
Market Cap328B
Beta0.56
PE Ratio (TTM)270.55
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.60 (2.94%)
Ex-Dividend Date2018-05-25
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Look at Allergan’s Valuation as of June 19
    Market Realist2 hours ago

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
    Motley Fool6 hours ago

    Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

    J&J's dividend is good. But these are even better.

  • Here’s how much Houston public companies spent on litigation in 2017
    American City Business Journals6 hours ago

    Here’s how much Houston public companies spent on litigation in 2017

    Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.

  • What’s the Latest on Teva’s Fremanezumab?
    Market Realist19 hours ago

    What’s the Latest on Teva’s Fremanezumab?

    Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.

  • TheStreet.com21 hours ago

    The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish

    is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.

  • Bloomberg22 hours ago

    Opioid Ruling Could Send  Purdue, Drugmakers to Court

    Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Foolyesterday

    3 Stocks That Are Absurdly Cheap Right Now

    When stocks become nonsensically priced due to irrational market decisions, investors should act on the opportunity.

  • Reutersyesterday

    FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA.

  • Markets Right Now: Stocks look to recover from early skid
    Associated Press2 days ago

    Markets Right Now: Stocks look to recover from early skid

    NEW YORK (AP) — The latest on developments in financial markets (all times local):

  • TheStreet.com2 days ago

    3 Great Stocks for Retirees to Own

    Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.

  • Reuters2 days ago

    After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.

  • Why Geron Corporation Stock Is Heading Higher Today
    Motley Fool2 days ago

    Why Geron Corporation Stock Is Heading Higher Today

    The company's EHA conference over the weekend has investors snapping up shares today.

  • UNF, Mayo experiment with rare 3-D microscope
    American City Business Journals2 days ago

    UNF, Mayo experiment with rare 3-D microscope

    The University of North Florida is temporarily housing a highly advanced microscope, the only one of its kind in North America.

  • Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
    Motley Fool3 days ago

    Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming

    Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?

  • Better Buy: Johnson & Johnson vs. Eli Lilly
    Motley Fool3 days ago

    Better Buy: Johnson & Johnson vs. Eli Lilly

    Which of these big pharma stocks has a better chance to outperform for your portfolio.

  • Better Buy: Pfizer Inc. vs. Johnson & Johnson
    Motley Fool3 days ago

    Better Buy: Pfizer Inc. vs. Johnson & Johnson

    How do these two big pharma stocks compare in a head-to-head match?

  • Financial Times3 days ago

    [$$] Global pharma bleeds talent to China start-ups

    Multinational drug companies in China are fighting to hold on to top talent as senior local staff leave to join a booming domestic biotechnology sector drawing record investment. $11.7bn of venture capital investment in 2017, more than double the $5.3bn invested in 2016, according to consultancy ChinaBio, with about $2.6bn going to drug developers. “I see clearly the opportunity for Chinese companies and for indigenous innovation for patients in China,” said Xiaobin Wu, who was Pfizer’s China manager from 2009 until he joined local cancer drug developer BeiGene last month.

  • Moody's5 days ago

    LifeScan Global Corporation -- Moody's downgrades LifeScan Global's term loan B rating to B2 from B1

    Moody's Investors Service ("Moody's) downgraded LifeScan Global Corporation's ("LifeScan") first lien term loan rating to B2 from B1. At the same time Moody's affirmed all other ratings of LifeScan as detailed below including the B2 Corporate Family Rating.

  • Barrons.com5 days ago

    [$$] Can Investment Performance Be Predicted?

    Morningstar’s annual investment conference in Chicago last week was noticeably different than in years past. The 30th iteration focused less on stocks, funds, and other investments, and instead emphasized technology and tools to analyze them. The three-day gathering also served up big-picture thinking from luminaries such as veteran investor and environmental evangelist Jeremy Grantham, and Nobel Prize–winning behavioral psychologist Danny Kahneman.

  • 7 Perfect Dividend Stocks
    InvestorPlace5 days ago

    7 Perfect Dividend Stocks

    Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.

  • Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
    Zacks5 days ago

    Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

    Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

  • 10 Best Stocks to Buy and Hold Forever
    InvestorPlace5 days ago

    10 Best Stocks to Buy and Hold Forever

    In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place. Conversely, the fact that Warren Buffett’s favorite holding period is “forever” and how he’s got a track record most investors would envy is just as telling. With that as the backdrop, here’s a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.

  • Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod
    Zacks5 days ago

    Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod

    The Dow traversed a tough week, suffering losses for three consecutive sessions.

  • Cramer floats idea for 'gloomy' ETF with Wall Street's mo...
    CNBC Videos2 days ago

    Cramer floats idea for 'gloomy' ETF with Wall Street's mo...

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.

  • Cramer floats idea for 'gloomy' ETF
    CNBC Videos2 days ago

    Cramer floats idea for 'gloomy' ETF

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.